Repletion of Ergothioneine in Patients With Kidney Failure

Stanford University

Status: Enrolling

Conditions: Esrd

Treatments: Other: Placebo; Dietary Supplement: Ergothioneine

Study type: Interventional

Funder types: Other

Identifiers

NCT06487546

75743

Details and patient eligibility

About

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Enrollment: 28 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• kidney failure receiving hemodialysis or peritoneal dialysis

Exclusion criteria

• blood transfusion within 90 days
• taking supplements which contain ergothioneine

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

28 participants in 2 patient groups, including a placebo group

Ergothioneine

Experimental group

Description:

Ergothioneine (range 5 mg to 25 mg) oral daily for up to 12 weeks

Treatment:

Dietary Supplement: Ergothioneine

Placebo

Placebo Comparator group

Description:

Matching placebo oral daily for up to 12 weeks

Treatment:

Other: Placebo